MRK reports portfolio transformation and pipeline advances

Merck said it has made significant progress in transforming its portfolio, with projected human health revenue rising to more than $70B by the mid-2030s. The company said its oncology and non-oncology pipelines are advancing, supported by new launches, robust clinical data and strategic investments aimed at long-term growth.